BioNTech : Speech of Dr. Sierk Poetting (COO/CFO)

VIRTUAL ANNUAL GENERAL MEETING 2021

June 22, 2021, at 2.00p.m.

Report of the Management Board - Dr. Sierk Poetting (CFO and COO)

Thank you Helmut and thank you Jens. I am very pleased that we can use the occasion of the Annual General Meeting to introduce our new, strengthened management team, a team and a collaboration which I look forward to be working with. Ladies and Gentlemen, as my colleague Ugur Sahin has already illustrated with our business update, 2020 has been a remarkable year for BioNTech. The development of our COVID-19 vaccine has been a significant milestone and I am pleased to provide you with an overview of the corresponding financial impact of the past financial year. The development has demonstrated that our corporate values form the basis of everything we do: We are innovative, passionate and united and bring those values into our everyday work. These values also contribute into our efforts toward being a responsible and sustainable corporation, a topic which we have addressed in the form of our recently issued corporate social responsibility report.

Today, I will give you an overview of the 2020 financial year by looking at some key information from our financial statements and our combined management report, which provides a brief overview of our operations, net assets and financial position during and as of the end of the last financial year. In addition, the latest developments during the first quarter in 2021 as well as a financial outlook for 2021 will form part of today's analysis. I will also go into details of our 2020 financial year capital transactions and finally will say something about the inter-company agreements on which a resolution is to be passed today.

1

Beyond the financial overview, I will provide an update on a topic that is very important to our various stakeholders and us. Leveraging our corporate values, as outlined in the beginning, have been used by us as a starting point to analyze and define our corporate social responsibility strategy. Therefore, I am pleased to conclude my speech today with some more insights into this topic as well.

Let us first turn to the financial statements and the combined management report.

The BioNTech Group, consisting of BioNTech SE and its subsidiaries - as my colleague Ugur Sahin has just explained - develops, manufactures and - following regulatory approval - markets individualized immunotherapies. Our analyses of financial results focus on the Group as a whole, rather than the individual legal entities that belong to it. Therefore, my explanations today as well as the slides generally focus on the consolidated key financial figures of the BioNTech Group prepared in accordance with International Financial Reporting Standards as adopted by the European Union. However, for your reference, some individual key financial figures of BioNTech SE prepared in accordance with the German Commercial Code are also illustrated.

Let us start on slide 23 with total revenues, which were estimated to be

1. million Euros during the 2020 financial year, compared to 108.6 million Euros during the 2019 financial year. Total revenues during the 2020 financial year included

1. million Euros of research & development revenues as well as 303.5 million Euros of commercial revenues.

Total revenues increased due to us recognizing revenues for the first time under our new collaboration agreements signed with Pfizer and Fosun Pharma to develop a COVID-19 vaccine, and ultimately led to the recognition of COVID-19 vaccine commercial revenues.

Newly generated COVID-19 vaccine commercial revenues significantly drove our total revenues. Slide 24 shows a breakdown of our commercial revenues. As a reminder, under the Pfizer collaboration, territories have been allocated between Pfizer and us based on marketing and distribution rights.

2

Our 2020 commercial revenues comprised an estimated amount of 188.5 million Euros, which represents our share of gross profit from COVID-19 vaccine sales in the Pfizer territory. Please note this is a net figure. As detailed in our consolidated financial statements, this figure was only estimated based on preliminary data shared between Pfizer and us and may be subject to adjustments as we receive final data on input parameters such as sales and transfer prices. Changes in our share of the collaboration partner's gross profit are recognized prospectively.

Our COVID-19 vaccine commercial revenues also included 61.4 million Euros of sales of products manufactured by us to Pfizer and 20.6 million Euros of direct COVID-19 vaccine sales to customers in our territory in Germany.

Now, returning to slide 23 and moving to cost of sales - these were estimated to be

59.3 million Euros during the 2020 financial year, compared to 17.4 million Euros during the 2019 financial year. The increase was driven by an estimated 35.6 million Euros of cost of sales, which was recognized for the first time with respect to our COVID-19 vaccine sales and include Pfizer's share of gross profit earned by us. Please note that cost of sales do not include costs relating to the production of pre-launch products, since those were expensed as research and development expenses in the period incurred.

In recent years, we have established a diversified portfolio of product candidates for the treatment of cancer, infectious diseases and other serious diseases based on different technologies. Accelerating the breadth of immunotherapy technologies will continuously result in significant costs in the future. These costs primarily include research and development expenses as well as general and administrative expenses to adequately support the growth of the BioNTech Group.

During the 2020 financial year, research and development expenses were

645.0 million Euros, compared to 226.5 million Euros during the 2019 financial year. The increase was primarily due to an increase in research and development expenses related to our COVID-19 vaccine program. Research and development expenses included our

3

share of expenses under the terms of the Pfizer collaboration agreement. As detailed in our consolidated financial statements, development costs are shared equally between Pfizer and us.

General and administrative expenses were 94.0 million Euros during the 2020 financial year, compared to 45.5 million Euros for the 2019 financial year. The increase was mainly due to higher expenses for purchased management consulting and legal services.

Driven by strengthening our exceptional team and the related increase in wages, benefits and social security expenses, both research and development as well as general and administrative expenses also increased during the 2020 financial year. Expanding our international team and being an attractive employer, are subjects of our core corporate objectives.

Following the receipt of authorization for emergency or temporary use or conditional marketing authorization of our COVID-19 vaccine, the recognition of deferred tax assets was reevaluated during the 2020 financial year. As of December 31, 2020, net deferred tax assets with respect to the accumulated tax losses and temporary differences of the German tax group were recognized with an income tax effect of 161.0 million Euros.

For the 2020 financial year, the BioNTech Group recorded a profit of 15.2 million Euros, compared to a 179.2 million Euro loss for the 2019 financial year.

We would like to emphasize that a net loss of 128.9 million Euros was recorded for the 2020 financial year in the individual financial statements of BioNTech SE, which were prepared in accordance with the German Commercial Code. As these financial statements form the basis of our appropriation of profit, we have, as in previous years, proposed to carry the loss forward to the next accounting period. Our Supervisory Board has accepted the proposal to carry the loss of the 2020 financial year forward which will increase the accumulated loss carryforward in the individual financial statements of BioNTech SE prepared in accordance with the German Commercial Code in the amount of 384.0 million Euros to 512.9 million Euros. In this context, I would now like to address

4

the matter of dividends, a topic that was frequently subject to questions in advance of this Annual General Meeting. In the next financial year, the Management Board and the Supervisory Board will examine, in accordance with the legal and statutory provisions, whether and in what amount a resolution on the distribution of dividends should be proposed to the Annual General Meeting.

As of December 31, 2020, the total equity amounted to 1,371.8 million Euros. Of the

1. million ordinary shares issued, 4.8 million were held as treasury shares. In comparison, as of December 31, 2019, the total equity amounted to 493.5 million Euros. Of the 232.3 million ordinary shares issued at that time, 5.5 million were held as treasury shares. I will describe the increase in share capital and the issuance of treasury shares following the financing transactions carried out during the 2020 financial year in more detail when I discuss the capital increases from authorized capital as well as the utilization of treasury shares. As a result of those successful financing transactions, we ended the 2020 financial year with cash and cash equivalents of 1,210.2 million Euros compared to

1. million Euros as of December 31, 2019, and strengthened our position to execute our strategy, which will be accelerated by growth in 2021.

In order to give you an overview of our financial development during the first quarter of the 2021 financial year, on slide 25, we have summarized some key information from our interim unaudited condensed consolidated financial statements which were filed with the SEC in our Quarterly Report on Form 6-K on May 10, 2021. Please note that these figures are unaudited and were prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Total revenues were estimated to be 2,048.4 million Euros for the first quarter of 2021, compared to 27.7 million Euros for the first quarter of 2020. Total revenues almost exclusively comprised revenues with respect to our COVID-19 vaccine program and increased due to rapidly increasing the supply of our COVID-19 vaccine worldwide. As just illustrated in detail for the 2020 financial year, the COVID-19 vaccine revenues include multiple components. During the first quarter of 2021, COVID-19 vaccine

5